

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

Sheet 1 of 23

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
JH		4,554,101		Hopp	11-19-1985	
		4,654,419		Vaughan	03-31-1987	
		4,707,358		Kieff	11-17-1987	
		4,784,942		Harley	11-15-1988	
		4,865,970		Brot, et al.	09-12-1989	
		5,312,752		Woltz, et al.	05-17-1994	
		5,354,691		Van Eden, et al.	10-11-1994	
		*5,637,454		Harley	06-10-1987	
		5,679,774		Wolf	10-21-1997	
		*5,723,283		Classen	03-03-1998	
JH		5,726,286		Alderson	03-10-1998	
		*5,874,531		Strominger, et al.	02-23-1999	
		5,965,353		Middeldorp	10-12-1999	

Examine
Signature

Sharon Fidy

Date Considered

5/3/2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 2 of 23	Attorney Docket Number	OMRF 161 CIP	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
SF		EP	0 113 431	B1	Yeshiva University	07-18-1984		
		EP	0 313 156	A1	Akzo N.V.	04-26-1989		
		WO	86/01210		Scripps Clinic Res.	02-27-1986		
		WO	88/09932		Amrad Corporation Ltd.	06-03-1988		
		WO	91/11718		Board of Regents of the University of Oklahoma	08-08-1991		
		WO	91/17171		Oklahoma Medical Research Foundation	11-14-1991		
		WO	91/18920		Neosystem	12-12-1991		
		*WO	93/21223		Board of Regents of the University of Oklahoma	10-28-1993		
		WO	94/02445		Yeda Research and Development Co. Ltd. at Weizmann Institute of Science	02-03-1994		
		WO	94/02509		Rijksuniversiteit Leiden	02-03-1994		
		WO	94/06912		Middeldorp	03-31-1994		
		WO	94/21669		Medclone, Inc.	09-29-1994		
		WO	96/37225		Oklahoma Medical Research Foundation	11-28-1996		

Examine Signature		Date Considered	5/18/2
-------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)



3 of 23

Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SHE		ALEXANDER, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," <i>Arth. And Rheum.</i> 35:176-189 (1992).	
		*ARBUCKLE, et al., "Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus," <i>Scand. J. Immunol.</i> 50(5):447-55 (1999).	
		BANERJEE, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," <i>Virology</i> 137:432-438 (1984).	
		BARAKET, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <i>Clin. Exp. Immunol.</i> 89:38-45 (1992).	
		BARAKET, et al., "Mapping of epitopes on U1 snRNP polypeptide A with synthetic peptides and autoimmune sera," <i>Clin. Exp. Immunol.</i> 86:71-78 (1991).	
		BARAKET, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," <i>Clin. Exp. Immunol.</i> 81:256-262 (1990).	
		BEN-CHETRIT, et al., "Isolation and Characterization of a cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <i>J. Clin. Inv.</i> 83:1284-1292 (1989).	
		BLANK, et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype," <i>J. Autoimmunity</i> 5:495-509 (1992).	
		BLANK, et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," <i>J. Autoimmunity</i> 1:683-591 (1988).	
SHE		BLANK, et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id +) and for Mouse Tuberculosis Antibody TB/68 (16/6 id +) <i>Clin. Immunol. Immunopathol.</i> 60:471-483 (1991).	

Examiner's
Signature

Sharon Felt

Date Considered

5/6/2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

Sheet 4 of 23

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SH		BLANK, et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotypic in Naive Mice," <i>J. Rheumatol.</i> 17:311-317 (1990).	
		BLANK, et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," <i>Clin. Exp. Immunol.</i> 79:443-447 (1990).	
		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," <i>Arch. Neurol.</i> 42:1798-1804 (1992).	
		BRAY, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis," <i>Arch. Neurology</i> 40:406-408 (1983).	
		BUYON, "Neonatal Lupus Syndrome," <i>Curr. Opin. In Rheum.</i> 6:523-529 (1994).	
		CHAMBERS, et al., "Genomic Structure and Amino Acid Sequence domains of the Human La Autoantigen," <i>J. Biol. Chem.</i> 263:18043-18051 (1988).	
		CHAMBERS, et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <i>Proc. Natl. Acad. Sci. USA</i> 82:2115-2119 (1985).	
		CHAN, et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <i>Nucl. Acids Res.</i> 17:2233-2244 (1989).	
SH		COHEN, "The Self, the World and Autoimmunity - Autoimmunity - In Which the Immune System Recognizes and Attacks the Self's Own Tissues - Is Not as Simple as it Seemed. Self-recognition Appears to be at the Heart of Health as Well as of Certain Diseases," <i>Scientific American</i> 258:52-60 (1988).	
		CRAFT, et al., "Murine and Drosophila B Proteins of SM snRNPS," <i>Mol. Biol. Rep.</i> 15:159 (1991).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	5/6/2
----------------------	---------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

5 of 23

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
8/1		CRONE, et al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," <i>Journal of Virology</i> 63(10):4172-4180 (1989).	
		CUNNINGHAM, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," <i>Journal of Immunology</i> 141(8):2760-2766 (1988).	
		DALLDORF, et al., "The Lymphomas of Brazilian Children," <i>J. Am. Med. Assn.</i> 208:1365-8 (1969).	
		DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163:351-360 (1991).	
		DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," <i>Am J. Med.</i> 92:453-454 (1992).	
		DEPOLO, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," <i>J. of Virology</i> 61:454-464 (1987).	
		DEUTSCHER, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," <i>Proc. Natl. Acad. Sci. USA</i> 85:9479-83 (1988).	
		DICKEY, "Human Autoantibody Producing Grafts in SCID Mice," presented to the Oklahoma Lups Association, Inc., Sept. 1, 1989.	
		DYRBERG & OLDSTONE, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," <i>Current Topics in Microbiology and Immunology</i> 130:25-37 (1986).	
8/1		ELKON, et al., "Epitope Mapping of Recombinant HeLa SmB and B' Peptides Obtained by the Polymerase Chain Reaction," <i>J. Immun.</i> 145:636-643 (1990).	

Examiner's Signature	<i>Sharon 706</i>	Date Considered	5/8/2
----------------------	-------------------	-----------------	-------

*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 6 of 23	Attorney Docket Number	OMRF 161 CIP	



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SH		ESQUIVEL, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," <i>J. Exp. Med.</i> 145:1250-1263 (1977).	
		EVANS & NIEDERMAN, "Epstein-Barr virus". in <i>Viral Infections in Humans</i> , 3rd ed. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989).	
		EVANS & ROTHFIELD, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:1127-1128 (1973).	
		EVANS, "E.B. Virus Antibody in Systemic Lupus Erythematosus" <i>Lancet</i> 1:1023-4 (1971).	
		EVANS, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 325-324 (1973).	
		EVANS, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus," <i>Lancet</i> 1:167-168 (1971).	
		FERRIS & DONALDSON, <i>Veterinary Microbiology</i> 18(3-4):243-258 (1988).	
		FINERTY, et al., "Immunization of Cottontop Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <i>Vaccine</i> 12:1180-1184 (1994).	
		FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," <i>J. Gen. Virol.</i> 73:449-453 (1992).	
SH		FOX, "Sjogren's Syndrome," <i>Current Opin. Rheum.</i> 7:409-416 (1995).	

Examiner's Signature	<i>Sharon Feb</i>	Date Considered	<i>5/3/02</i>
----------------------	-------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 7 of 23	Attorney Docket Number	OMRF 161 CIP	



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SF		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," <i>J. Immunol.</i> 137:3162-3168 (1986).	
		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," <i>J. Rheumatol.</i> 19:18-24 (1992).	
		FRICKE, et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," <i>Intern. Immunol.</i> 2:225-230 (1990).	
		FRITZ, et al., "Small Nuclear U-Ribonucleoproteins in <i>Xenopus Laevis</i> Development," <i>J. Mol. Biol.</i> 178:273-285 (1984).	
		GAITHER, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity," <i>J. Clin. Invest.</i> 79:841-846 (1987).	
		GAITHER, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" <i>Peptides Biol. Fluids</i> 33:413-416 (1985).	
		GALLIONE, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," <i>Virology</i> 39:529-535 (1981).	
		*GAUTAM, et al., "A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis," <i>J. Immunol.</i> 161:60-64 (1998).	
		GERGELY, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus," <i>Lancet</i> 1:325-326 (1973).	
SF		GEYSEN, et al., "Strategies for Epitope Analysis Using Peptide Synthesis," <i>J. of Immunol. Meth.</i> 102:259-274 (1987).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	5/3/02
----------------------	---------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 <p>Use as many sheets as necessary)</p>		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 8 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAF		GEYSEN, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002 (1984).	
		GRABOWSKI, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO," <i>Nucleic Acids Research</i> 19(15):4297 (1991).	
		GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84:171-177 (1995).	
		GULDNER, et al., "Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera." <i>The Journal of Immunology</i> 141(2):469-475 (1988).	
		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," <i>Cancer Res.</i> 56:969-972 (1996).	
		HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," <i>Ann. N. Y. Acad. Sci.</i> 724:148-156 (1996).	
		HAHN, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" <i>Springer Seminars in Immunopathology</i> , 7(1):25-34 (1984).	
	HARDGRAVE, et al, "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <i>Arthritis and Rheumatism</i> 36(7):962-970 (1993).		
	HARLEY & GAITHER, "Autoantibodies" <i>Rheum. Dis. Clin. N. Amer.</i> 14:43-56 (1992).		
SAF		HARLEY & JAMES, "Review Articles: Autoepitopes in Lupus," <i>J. Lab. Clin Med.</i> 126(6):509-516 (1995).	

Examiner's Signature		Date Considered	5/8/2
----------------------	---	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 1 of 23		Attorney Docket Number	OMRF 161 CIP

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SA		*HARLEY, et al., "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," <i>Arthritis Rheum.</i> 42(8):1782-3 (1999).	
		HARLEY, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjogren's Syndrome," <i>Science</i> 232:1145-1147 (1986).	
		HARLEY, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 29:196-206 (1986).	
		HERBERT, et al., <i>Dictionary of Immunology</i> 3 rd Ed. Blackwell Scientific Publications Oxford UK page 14 (1985).	
		HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," <i>Nature Med.</i> 2:551-555 (1996).	
		HINTERBERGER, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs," <i>J. Biol. Chem.</i> 258:2604-2613 (1983).	
		HOLLINGER, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus," <i>Bact. Proc.</i> 131:174 (1970).	
		HORSFALL, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," <i>J. of Autoimmun.</i> 4:165-176 (1991).	
		HUANG, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," <i>Scand. J. Immunol.</i> 41:220-228 (1995).	
SA		HUANG, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," <i>J. Invest. Med.</i> 43:151-158 (1995).	

Examiner's Signature		Date Considered	5/8/2
----------------------	--	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

10 of 23

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAH		HURD, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid," <i>Arthritis Rheum.</i> 13:724-733 (1970).	
		INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," <i>J. Infect. Dis.</i> 164:22-28 (1991).	
		ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," <i>Immunol. Cell Biol.</i> 73:463-468 (1995).	
		JAMES & HARLEY, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns," <i>J. Immunol.</i> 4018-4026 (1994).	
		JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," <i>J. Immunol.</i> 148:2074-2079 (1992).	
		JAMES & HARLEY, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C," <i>Clin. And Exp. Rheum.</i> 13:299-305 (1995).	
		JAMES & HARLEY, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C," <i>Clinical Res.</i> 41(2):PA393 (1993).	
		*JAMES & HARLEY, "A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice," <i>J. Immunol.</i> 160(1):502-8 (1998).	
		*JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," <i>J. Clin. Invest.</i> 100:3019-26 (1997).	
		*JAMES, et al., "Lupus humoral autoimmunity after short peptide immunization," <i>Ann. N. Y. Acad. Sci.</i> 815:124-7 (1997).	

Examiner's Signature	<i>Sharon F. [Signature]</i>	Date Considered	5/8/2
-------------------------	------------------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	OMRF 161 CIP



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SHZ		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," <i>J. Exp. Med.</i> 181:453-461 (1995).	
		JAMES, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <i>Scand. J. Immunol.</i> 39:557-566 (1994).	
		JAMES, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization," <i>Arthritis Rheum.</i> 38:S226 (1995).	
		JAMES, et al., "Lupus Humoral Autoimmunity After Short Peptide Immunization," <i>Arthritis Rheum.</i> 39:S216 (1996).	
		JAMES, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL <i>lpr/lpr</i> Antibodies," <i>Clin. Exp. Immunol.</i> 98:419-426 (1994).	
		KALUSH, et al., "Neonatal Lupus Erythematosus with Cadian Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus," <i>J. of Clin. Immunol.</i> 14:314-321 (1994).	
		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 10:327-332 (1992).	
		KAUFMAN, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Anklosing spondylitis Pathogenesis," <i>Arthritis Rheum.</i> 39:S298 (1996)	
		KIEFF & LIEBOWITZ, Epstein-Barr virus and its replication. In <i>Virology</i> , 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990).	
SAE		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <i>Immunol. Lett.</i> 17:249-252 (1988).	

Examiner's Signature	<i>Sharon Folg</i>	Date Considered	<i>SHZ</i>
----------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 12 of 23	Attorney Docket Number	OMRF 161 CIP	



OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAX		KLIPPEL, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus," <i>Lancet</i> , 2:1057-1058 (1973).	
		KURILLA, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," <i>Cell</i> 34:837-845 (1983).	
		KUZUSHIMA, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection," <i>Clin. Exp. Immunol.</i> 103:192-198 (1996).	
		LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," <i>Neurology</i> 35:435-438 (1985).	
		LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," <i>Clin. Invest. Med.</i> 17:621-625 (1994).	
		LEE, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," <i>Am. J. of Med.</i> 83:793-796 (1987).	
		LEE, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus," <i>J. Investigative Dermatology</i> 107(1):225-228 (1996).	
		LEFF, "Maverick Herpes Receptor Sparks Search for KS Drug," <i>Bio World Today</i> 8(17):1 (1997).	
		LEHMAN, et al., "Spreading of T-Cell Autoimmunity to Cryptic Determinants of an Autoantigen," <i>Nature</i> 356:155-157 (1992).	
SAX		LERNER & STEITZ, "Antibodies to Small Nuclear PNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus," <i>Proc. Natl. Acad. Sci. USA</i> 76:5495-5499 (1979).	

Examiner's Signature	<i>Sharon F. [Signature]</i>	Date Considered	5/6/2
----------------------	------------------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 13 of 23	Attorney Docket Number	OMRF 161 CIP	



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SH		LERNER, et al., "Are snRNPs Involved in Splicing?" <i>Nature</i> 283:220-224 (1980).	
		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," <i>Nature</i> 375:685-688 (1995).	
		MADDISON, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," <i>Arthritis Rheum.</i> 20:819-824 (1977).	
		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," <i>Am. J. Med.</i> 96:97 (1994).	
		MANFREDI, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <i>J. Lab. Clin. Med.</i> 120:13-21 (1992).	
		MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," <i>Am. J. Med.</i> , 90:286-294 (1991).	
		MATTER, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <i>Arthritis Rheum.</i> 25:1278-1283 (1982).	
		MATTIOLI, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the SM and RNA protein (MO) Systems in SLE Sera," <i>J. Immunol.</i> 110:1318-1324 (1973).	
		MCALLISTER, et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," <i>EMBO J.</i> 8:1177-1181 (1989).	
SH		MENDLOVIC, et al., "Induction of an SLE-Like Disease in Mice by a Common Anti-DNA Idiotypic," <i>Proc. Natl. Acad. Sci. USA</i> 85:2260-2264 (1988).	-

Examiner's Signature	<i>Sharon Feld</i>	Date Considered	5/8/2
----------------------	--------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

Sheet 14 of 23

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SA		MENDLOVIC, et al., "The Genetic Regulation of the Induction of Experimental SLE," <i>Immunology</i> 69:228-236 (1990).	
		MENDLOVIC, et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," <i>Eur. J. Immunol.</i> 19:729-732 (1989).	
		MILLER, et al., "The Role of an Autoantigen, Histidyl-tRNA Synthetase, in the Induction and Maintenance of Autoimmunity," <i>Proc. Natl. Acad. Sci. USA</i> 87:9933-9937 (1990).	
		MIYASHITA, et al., "A Novel Form of Epstein-Barr Virus Latency in Normal B Cells In Vivo," <i>Cell</i> , 80:593-601 (1995).	
		MORGAN, "Epstein-Barr Virus Vaccines," <i>Vaccine</i> 10:563-571 (1992).	
		MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," <i>J. Med. Virol.</i> 29:74-78 (1989).	
		MORLAND, et al., "Anti-idiotypic and Immunosuppressant Treatment of Murine Lupus," <i>Clin. Exp. Immunol.</i> 83(1):126-132 (1991).	
		MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," <i>Gastroenterol. Jpn.</i> 27(6):751-758 (1992).	
		MOSIER, et al., "Transfer of a functional human immune system to mice with severe combined immunodeficiency," <i>Nature</i> 335:256-259 (1988).	
SA		MUNVES, et al., "Antibodies to Sm and RNP," <i>Arthritis Rheum.</i> 26:848-853 (1983).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	5/6/2
----------------------	---------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 23

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAF		*NICHOLSON, "A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens," <i>Proc. Natl. Acad. Sci. USA</i> 94:9279-9284 (1997).	
		NEWELL & STEVENS, "E.B. Virus Antibody in Systemic Lupus Erythematosus," <i>Lancet</i> 1:652 (1971).	
		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," <i>Br. J. Rheum.</i> 33:317-322 (1994).	
		OHOSONE, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen: Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," <i>Proc. Natl. Acad. Sci. USA</i> 86:4249-4253 (1989).	
		PALFI, et al, "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," <i>Nucleic Acids Res.</i> 17:1445-1458 (1989).	
		PETERSEN, et al, "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 33:993-1000 (1990).	
		PETTERSSON, et al., "The Structure of Mammalian Small Nuclear Ribonucleoproteins," <i>J. Biol. Chem.</i> 259:5907-5914 (1984).	
		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," <i>Ophthalmology</i> 97:976-984 (1990).	
		PFLUGFELDER, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," <i>Am. J. Pathol.</i> 143:49-64 (1993).	
SAF		PHILLIPS & CHRISTIAN, "Myxovirus Antibody Increases in Human Connective Tissue Disease," <i>Science</i> 168:982-4 (1970).	

Examiner's Signature	<i>Shane Fdg</i>	Date Considered	<i>8/5/02</i>
----------------------	------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

Sheet 16 of 23

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SA		PHILLIPS, et al., "Viruses and Systemic Lupus Erythematosus," <i>Lancet</i> 1:1449 (1973).	
		QUALTIERE & PEARSON, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-1 Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Produced Culture Activated with Tumor-Promoting Agent (TPA)," <i>Virology</i> 102:360-369 (1980).	
		QUERY, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," <i>Cell</i> 57:89-101 (1989).	
		RAVIRAJAN & STAINES, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" <i>Immunology</i> 74:342-347 (1991).	
		REICHLIN, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," <i>Clin. Exp. Immunol.</i> 83:286-290 (1991).	
		REICHLIN, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," <i>Arth. And Rheum.</i> 37:1698-1703 (1994).	
		RENZ, et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in <i>Escherichia coli</i> and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," <i>Clin. Chem.</i> 35:1861-1863(1989).	
		REUTER, et al., "Immunization of Mice with Purified U1 Small Nuclear Ribonucleoprotein (RNP) Induces a Pattern of Antibody Specificities Characteristic of the Anti-Sm and Anti-RNP Autoimmune Response of Patients with Lupus Erythematosus, As Measured by Monoclonal Antibodies," <i>PNAS</i> 83:8689-8693 (1986).	
		RHODES, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Glycine-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen," <i>J. Exp. Med.</i> , 165:1026-1040 (1987).	
SA		RHODES, et al., "Human Immune Responses to Synthetic Peptides from the Epstein-Barr Nuclear Antigen," <i>J. Immunol.</i> 134:211-216 (1985).	

Examiner's Signature	<i>Sharon Fobg</i>	Date Considered	5/6/2
----------------------	--------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904	
		Filing Date	February 9, 2000	
		First Named Inventor	John B. Harley	
		Group Art Unit		
		Examiner Name		
17	of	23	Attorney Docket Number	OMRF 161 CIP



OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SA		ROKEACH, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis," <i>J. Biol. Chem.</i> , 264:5024-30 (1989).	
		ROKEACH, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," <i>Proc. Natl. Acad. Sci. USA</i> 85:4832-36 (1988).	
		ROSE, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. ed. <i>Autoimmunity Genetic Immunologic Virologic, and Clinical Aspects</i> . New York: Academic Press, 63-87 (1977).	
		ROSE, et al., "Studies on Experimental Thyroiditis," <i>Ann. NY Acad. Sci.</i> 124:201-209 (1965).	
		ROSE, et al., "T-Cell Regulation in Autoimmune Thyroiditis," <i>Immunol. Reviews</i> 55:229-314 (1981).	
		SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA 1," <i>Eur. J. Immunol.</i> 23:1146-1152 (1993).	
		SAITO, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with Sjogren's Syndrome," <i>J. Exp. Med.</i> , 169:2191-2198 (1989).	
		SASAKI, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin," <i>The Journal of Immunology</i> 142(4):1159-1165 (1989).	
		SCHAAK, "Molecular Mimicry in HLA-B-27-Related Arthritis," <i>Annals of Internal Medicine</i> 111(7):581-591 (1989).	
SA		SCHMAUSS, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)," <i>Nuc. Acid Res.</i> 17:1733-43 (1989).	

Examiner's Signature	<i>Shawn F. [Signature]</i>	Date Considered	5/6/2
----------------------	-----------------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 1 of 23		Attorney Docket Number	OMRF 161 CIP

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAH		SCOFIELD, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies," <i>Lancet</i> , 345:1542-1544 (1995).	
		SCOFIELD, "A Common Autoepitope Near the carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," <i>Journal of Clinical Immunology</i> 11(6):378-388 (1991).	
		SCOFIELD, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 14:321-330 (1996).	
		SCOFIELD, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen Results in Anti-Ro Ribonucleoprotein Autoimmunity," <i>J. Immunology</i> 4059-4066 (1996).	
		SCOFIELD, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Proc. Natl. Acad. Sci. USA</i> , 88:3343-3347 (1991).	
		SCOFIELD, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus," <i>Arthritis & Rheumatism</i> 39(10):1664-1688 (1996).	
		SCOFIELD, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Homologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <i>Clinical Research</i> 38(2):316A, (1990).	
		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67:2253-2258 (1986).	
		SHARPE, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto-Immune Antigen and Specifically Reaching with Human Anti-Sm Auto-," <i>FEBS Lett.</i> 250:585-590 (1989).	
SP		SHOENFELD, et al. "Modulation of experimental SLE induced in naïve mice by a pathogenic anti-DNA idotype (16/6 Id.)," <i>Proceedings of the Second International Conference on Systemic Lupus Erythematosus Tokyo, Japan Professional Postgraduate Services</i> 83 (1989).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	8/6/2
----------------------	---------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 19 of 23	Attorney Docket Number	OMRF 161 CIP	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SP		SHOENFELD, et al., "Pathogenic idiotypes of autoantibodies in autoimmunity: lessons from new experimental models of SLE," <i>FASEB J.</i> 4:2646-2651 (1990).	
		SILLIKENS, et al., "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins," <i>EMBO Journal</i> 6:3841-3848 (1987).	
		SILLIKENS, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals," <i>Nucleic Acids Res.</i> 16:8307-21 (1988).	
		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," <i>Digestive Dis. Sci.</i> 39:15-18 (1994).	
		SPRITZ, et al., "The Human U1-70K s.n. RNP Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding," <i>Nucleic Acid Res.</i> 15:10373-91 (1987).	
		STURGESS, et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La," <i>J. Immun.</i> 3212-3218 (1988).	
		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," <i>Ann. Neurol.</i> 17:371-377 (1985).	
		SUZUKI, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors," <i>J. Exp. Med.</i> 182:477-486 (1995).	
		TAKEDA, et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," <i>Chem. Abstracts</i> 116(1): ab. No. 4803a (January 6, 1992).	
SP		TAN, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 25:1271-1277 (1982).	

Examiner's Signature	<i>Sharon Foley</i>	Date Considered	5/8/2
----------------------	---------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAF		TAN, et al., "Characteristics of a Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," <i>J. Immunol.</i> 96:464-471 (1966).	
		TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 36:827-835 (1993).	
		<u>The Medical Letter on Drugs and Therapeutics</u> 37(951):55-57 (June 23, 1995).	
		THEISSEN, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," <i>EMBO J.</i> 5:3209-17 (1986).	
		TIGBE, Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes, presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989).	
		TINCANI, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotype," <i>Clinical and Exp. Rheum.</i> 11:129-134 (1993).	
		TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," In <u>Lacrimal Gland, Tear Film, and Dry Eye Syndrome</u> . (D.A. Sullivan, ed.) pp 647-650 (Plenum Press, New York 1994).	
		TSAI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," <i>Int. Arch. Allergy Immunol.</i> 106:235-240 (1995).	
		TSUZUKA, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S1 ^{1,2} " <i>J. Immunol.</i> 156:1668-1675 (1996).	
SAF		TZARTOS, et al., "The Main Immunogenic region of the Acetylcholine Receptor. Structure and Role in Myasthenia Gravis," <i>Autoimmunity</i> 8:259-270 (1991).	

Examiner's Signature	<i>Sharon F. [Signature]</i>	Date Considered	5/8/2
----------------------	------------------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

21 of 23

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SP		VAN DAM, et al., "Cloned Human snRNP Proteins B and B' Differ Only in Their Carboxy-Terminal Part," <i>EMBO J.</i> 8(12):3853-3860 (1989).	
		*VANDENBARK, et al., "Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide," <i>Immunology and Cell Biology</i> 76:83-90 (1998).	
		VAN VENROOIJ, et al., "B Cell Epitopes on Nuclear Autoantigens," <i>Arthritis and Rheumatism</i> 37(5):608-616 (1994).	
		VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," <i>Clin. Exp. Immunol.</i> , 75:359-364 (1989).	
		VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," <i>J. Autoimmunity</i> 2:439-448 (1989).	
		VIRJI & HECKELS, "Location of a Blocking Epitope on Outer-membrane Protein III of Neisseria Gonorrhoeae by Synthetic Peptide Analysis," <i>J. of Gen. Microbiol.</i> 135:1895-1899 (1989).	
		VOLLER & BIDWELL, "Enzyme-Linked Immunosorbent Assay," <i>Manual of Clinical Laboratory Immunology</i> (Chapter 17) (1986).	
		WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," <i>Drugs</i> 47:153-205 (1994).	
		WAITE, et al., "Anti-Jo-1 antibodies are Directed at an Evolutionarily-conserved Conformational Site on Human Histidyl-tRNA Synthetase," <i>Mol. Cell Biol. Autoantibodies Autoimm.</i> 100-101 (1989).	
SP		WALTUCK & BUYON, "Autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," <i>Ann. Intern. Med.</i> 120:544-551 (1994).	

Examiner's
Signature

Sharon Kelly

Date Considered

5/6/2

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/500,904
		Filing Date	February 9, 2000
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 22 of 23	Attorney Docket Number	OMRF 161 CIP	



OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAC		WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," <i>Med. Hypotheses</i> 25:93-97 (1988).	
		WATSON, et al., "Certain Properties Make Substances Antigenic," in <i>Molecular Biology of the Gene</i> , Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).	
		WHITTINGHAM, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," <i>Med. Hypothesis</i> , 22:373-386 (1987).	
		WILLIAMS, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," <i>J. Autoimmunity</i> 3:715-725 (1990).	
		WILSON, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon-α2b," <i>Blood</i> , 87:4531-4537 (1996).	
		WINFIELD, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," <i>Arthritis Rheum.</i> 21:289-294 (1978).	
		WITEBSKY, et al., "Chronic Thyroiditis and Autoimmunization," <i>J. Am. Med. Assoc.</i> 164:1439-1447 (1957).	
		XIE & SNYDER, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus," <i>Proc. Natl. Acad. Sci.</i> 92:1639-1643 (1995).	
		YAMAMOTO, et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <i>J. Immun.</i> 140:311-317 (1988).	
SAC		YOKOCHI, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus," <i>J. Rheumatol.</i> 16:1029-1032 (1989).	

Examiner's Signature	<i>Sharon F. G.</i>	Date Considered	5/8/2
----------------------	---------------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



Complete if Known

Application Number	09/500,904
Filing Date	February 9, 2000
First Named Inventor	John B. Harley
Group Art Unit	
Examiner Name	
Attorney Docket Number	OMRF 161 CIP

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
SAF		ZELLER, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiled snRNA-Binding Proteins During Oogenesis and Early Development in Xenopus laevis," <i>Cell</i> 32:425-434 (1983).	

Examiner's Signature		Date Considered	5/8/2
-------------------------	--	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.